Zymeworks Inc. (ZYME)
USD 11.49
(2.13%)
USD 11.49
(2.13%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -138.05 Million USD | -205.77% |
| 2022 | 130.52 Million USD | 160.53% |
| 2021 | -215.63 Million CAD | -15.02% |
| 2020 | -187.46 Million USD | -23.9% |
| 2019 | -151.3 Million USD | -356.73% |
| 2018 | -33.12 Million USD | -268.16% |
| 2017 | -8.99 Million USD | 76.24% |
| 2016 | -37.86 Million USD | -89.7% |
| 2015 | -19.96 Million USD | -56.57% |
| 2014 | -12.74 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -25.59 Million USD | 32.28% |
| 2024 Q1 | -37.8 Million USD | -61.4% |
| 2024 Q3 | -34.2 Billion USD | -33.62% |
| 2023 Q3 | -33.23 Million USD | 38.58% |
| 2023 Q1 | -27.28 Million USD | -108.54% |
| 2023 Q2 | -54.11 Million USD | -98.36% |
| 2023 FY | -138.05 Million USD | -205.77% |
| 2023 Q4 | -23.42 Million USD | 29.53% |
| 2022 Q2 | -65.82 Million USD | 9.44% |
| 2022 FY | 130.52 Million USD | 160.53% |
| 2022 Q4 | 319.39 Million USD | 734.25% |
| 2022 Q3 | -50.35 Million USD | 23.49% |
| 2022 Q1 | -72.68 Million USD | -77.94% |
| 2021 Q4 | -40.84 Million CAD | 32.99% |
| 2021 Q2 | -68.88 Million USD | -53.3% |
| 2021 FY | -215.63 Million CAD | -15.02% |
| 2021 Q1 | -44.93 Million USD | -19.68% |
| 2021 Q3 | -60.96 Million USD | 11.5% |
| 2020 Q2 | -40.34 Million USD | -12.46% |
| 2020 Q1 | -35.88 Million USD | 51.35% |
| 2020 Q4 | -37.54 Million USD | 49.05% |
| 2020 FY | -187.46 Million USD | -23.9% |
| 2020 Q3 | -73.69 Million USD | -82.64% |
| 2019 Q1 | -14.55 Million USD | -270.51% |
| 2019 FY | -151.3 Million USD | -356.73% |
| 2019 Q4 | -73.75 Million USD | -119.74% |
| 2019 Q3 | -33.56 Million USD | -14.04% |
| 2019 Q2 | -29.43 Million USD | -102.24% |
| 2018 Q3 | -19.53 Million USD | -869.0% |
| 2018 Q4 | 8.53 Million USD | 143.69% |
| 2018 FY | -33.12 Million USD | -268.16% |
| 2018 Q1 | -20.11 Million USD | -160.33% |
| 2018 Q2 | -2.01 Million USD | 89.98% |
| 2017 Q1 | -16.4 Million USD | -55.67% |
| 2017 Q2 | -9.23 Million USD | 43.72% |
| 2017 Q3 | -16.69 Million USD | -80.86% |
| 2017 Q4 | 33.33 Million USD | 299.65% |
| 2017 FY | -8.99 Million USD | 76.24% |
| 2016 Q3 | -11.05 Million USD | -69.08% |
| 2016 Q2 | -6.53 Million USD | 32.89% |
| 2016 Q1 | -9.73 Million USD | -23.0% |
| 2016 FY | -37.86 Million USD | -89.7% |
| 2016 Q4 | -10.53 Million USD | 4.64% |
| 2015 FY | -19.96 Million USD | -56.57% |
| 2015 Q4 | -7.91 Million USD | 0.0% |
| 2014 FY | -12.74 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| ADC Therapeutics SA | -165.98 Million USD | 16.829% |
| Alto Neuroscience, Inc. | -37.8 Million USD | -265.133% |
| Annovis Bio, Inc. | -45.03 Million USD | -206.546% |
| Biohaven Pharmaceutical Holding Company Ltd. | -436.05 Million USD | 68.34% |
| Ginkgo Bioworks Holdings, Inc. | -864.4 Million USD | 84.029% |
| Nuvation Bio Inc. | -99.82 Million USD | -38.299% |
| Nuvation Bio Inc. | -99.82 Million USD | -38.299% |
| Arcus Biosciences, Inc. | -340 Million USD | 59.396% |